Merck decides it's smart to leave ALEC

Another drug company is bailing on ALEC, the group that gets business leaders together with mostly Republican state lawmakers to write so-called model legislation, generally around business. The American Legislative Exchange Council has been in the spotlight this year for support of tougher voter ID laws and self-defense gun laws. A Merck ($MRK) spokeswoman tells that Merck reviews its memberships each fall and decides which ones meet its budget and policy priorities, and ALEC didn't make the cut this year. Johnson & Johnson ($JNJ) dropped its membership in June. Pfizer found itself the subject of criticism earlier this year for its membership in ALEC, which has been accused of inappropriate lobbying. Story | More

Suggested Articles

Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.

Riival generics makers are squashing long-running lawsuits over their own versions of Sanofi's big-selling blood thinner Lovenox.

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.